Japan – Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease

New LEQEMBI CompanionTM program released to broaden practical resources for clients throughout the treatment journey, consisting of Nurse Educators who can offer clients with injection training, and an injection tracking tool and more
LEQEMBI IQLIK, authorized by the U.S. FDA in August 2025, is the very first and just anti-amyloid treatment to provide an at-home injection after preliminary treatment of 18 months

TOKYO and CAMBRIDGE, Mass., October 8, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) revealed today that lecanemab-irmb subcutaneous injection (U.S. trademark name: LEQEMBI ® IQLIKTM) is now offered in the U.S. as an upkeep dosing routine for the treatment of Alzheimer’s illness (ADVERTISEMENT) in clients with Mild Cognitive Impairment (MCI) or moderate dementia phase of illness (jointly described as early advertisement). After 18 months of LEQEMBI (lecanemab-irmb) intravenous (IV) treatment at 10 mg/kg every 2 weeks, clients might either continue IV infusions at 10 mg/kg as soon as every 4 weeks or begin the brand-new weekly 360 mg subcutaneous injection utilizing the LEQEMBI IQLIK autoinjector.

Eisai and Biogen have actually likewise released the LEQEMBI CompanionTM program, an effort rooted in both business’ dedication to supplying access to LEQEMBI and resources for individuals coping with early Alzheimer’s illness. The program intends to supply broadened resources that support clients throughout their LEQEMBI treatment journey, from initiation through upkeep treatment.

In addition to the existing resources currently offered (e.g., assist with understanding insurance protection and prospective out-of-pocket expenses and recognizing financial backing programs), the brand-new LEQEMBI Companion program will now use clients:

– Injection education through Nurse Educators either in-person or essentially to offer clients with training on injecting their upkeep dosage utilizing the LEQEMBI IQLIK (nurse teachers train on the gadget just; clients must go over any treatment-related concerns with their medical professional).

– A welcome set that consists of instructional resources to assist clients and care partners understand what to anticipate, get ready for at-home injections, and more.

Created to function as a digital option to assist assistance clients and care partners along their treatment journey, the LEQEMBI Companion app was established with Medisafe, a digital client engagement and medication management platform. From academic details about the injection procedure to a tool for tracking where and when injections happen, the LEQEMBI Companion app uses resources and more all in one location. Clients can go to LEQEMBI.com/ CompanionAppSignUp to start.

To even more support access to LEQEMBI for particular clients who require assistance spending for their medications, Eisai’s Patient Assistance Program (PAP) will offer LEQEMBI and LEQEMBI IQLIK at no charge, for qualified uninsured and underinsured clients, who fulfill monetary requirement and other program requirements.

For more information, or if you are currently registered and have concerns, see LEQEMBI.com/ PatientSupport or call 1-833-4-LEQEMBI (1-833-453-7362), Monday-Friday, 8 a.m. to 8 p.m. Eastern Time.

Advertisement is a progressive, ruthless illness defined by development of protein deposits referred to as plaques made from amyloid-beta aggregates and neurofibrillary tangles made from tau protein in the brains of individuals dealing with advertisement. It is brought on by a constant underlying neurotoxic procedure that starts before amyloid plaque build-up and continues after plaque removal.1-3 The information reveal that amyloid-beta protofibrils and tau tangles play functions in the neurodegeneration procedure,3,4 and just LEQEMBI battles advertisement in 2 methods– targeting both amyloid plaque and protofibrils *, which can affect tau downstream.

Due to the reaccumulation of advertisement biomarkers and go back to placebo rate of decrease after treatment is stopped,4,5 continuing upkeep treatment after the preliminary 18-month treatment is vital to slow the development of advertisement and extend the restorative advantages, assisting clients preserve who they are for longer.

The schedule of LEQEMBI IQLIK in the U.S. uses clients and care partners the capability to utilize the gadget at home, reducing treatment time, and offering an alternative to continue treatment without having to stress about checking out an infusion. The LEQEMBI IQLIK likewise has the possible to minimize health care resources related to IV upkeep dosing, such as preparation for infusion and nurse tracking, while increasing infusion capability for brand-new qualified clients to start initiation treatment and improving the total advertisement treatment path.

Eisai works as the lead for lecanemab’s advancement and regulative submissions internationally with Eisai and Biogen co-commercializing and co-promoting the item and Eisai having last decision-making authority.

* Protofibrils are believed to be the most harmful Aβ types that add to mental retardation in advertisement and play a significant function in the cognitive decrease of this progressive and destructive illness. Protofibrils can trigger neuronal and synaptic damage in the brain, which can consequently negatively impact cognitive function through numerous systems.4 The system by which this takes place has actually been reported not just by increasing the development of insoluble Aβ plaques, however likewise by straight destructive signaling in between nerve cells and other cells. It is thought that minimizing protofibrils might decrease neuronal damage and cognitive disability, possibly avoiding the development of advertisement.5

For more information, please go to: https://www.eisai.com/news/2025/pdf/enews202571pdf.pdf